NCT07088354 Deep Learning Model Predicts Pathological Complete Response of Esophageal Squamous Cell Carcinoma Following Neoadjuvant Immunochemotherapy
| NCT ID | NCT07088354 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tongji Hospital |
| Condition | Esophageal Squamous Cell Carcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2025-03-01 |
| Primary Completion | 2026-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2025-03-01 with a primary completion date of 2026-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to develop and validate a deep learning model to predict pathological complete response (pCR) in patients with esophageal squamous cell carcinoma who have undergone neoadjuvant immunochemotherapy. Clinical, imaging, and pathological data from previously treated patients will be collected and analyzed. The model is expected to assist in predicting treatment outcomes and guide personalized therapeutic strategies.
Eligibility Criteria
Inclusion Criteria: 1. Pathologically confirmed esophageal squamous cell carcinoma (ESCC). 2. Received at least one cycle of neoadjuvant chemotherapy combined with immunotherapy. 3. Underwent contrast-enhanced chest CT before initiation of neoadjuvant treatment. 4. Underwent contrast-enhanced chest CT after completion of neoadjuvant treatment and prior to surgery. Exclusion Criteria: 1. Diagnosis of other malignancies. 2. Received other anti-tumor therapies before or during neoadjuvant chemo-immunotherapy. 3. Incomplete clinical data. 4. Poor-quality CT imaging.
Contact & Investigator
Yangkai Li, MD, PhD
PRINCIPAL INVESTIGATOR
Tongji Hospital
Frequently Asked Questions
Who can join the NCT07088354 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Esophageal Squamous Cell Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07088354 currently recruiting?
Yes, NCT07088354 is actively recruiting participants. Contact the research team at doclyk@163.com for enrollment information.
Where is the NCT07088354 trial being conducted?
This trial is being conducted at Wuhan, China.
Who is sponsoring the NCT07088354 clinical trial?
NCT07088354 is sponsored by Tongji Hospital. The principal investigator is Yangkai Li, MD, PhD at Tongji Hospital. The trial plans to enroll 300 participants.